News
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. The drug was found to reduce the risk of a patient's ...
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. The drug was found to reduce the risk of a patient's ...
The FDA expanded approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. The decision will free up access to the medication for tens ...
Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the U.S. Food and Drug Administration's expanded approval of the treatment ...
WEDNESDAY, Sept. 18, 2024 (HealthDay News) -- Women with early stage breast cancer may now take Kisquali, a medication already approved for advanced disease, following the U.S. Food and Drug ...
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration approved ...
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. The drug was found to reduce the risk of a patient's ...
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to treat patients with earlier stage cancer, Novartis said.
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. The drug was found to reduce the risk of a patient's ...
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. The drug was found to reduce the risk of a patient's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback